Veligrotug

Ethyreal will share more information on its asset at the Endocrine Society’s 2026 Annual Meeting. \n Ethyreal Bio has exited stealth with $101 million in funding, joining the queue of companies preparing to challenge Amgen’s Tepezza.Backed by series A and B round investors, including Atlas Venture and Medicxi Ventures, the Massachusetts-based biotech has quietly advanced an anti-TSHR antibody to the cusp of clinical development. A first-in-human trial of the asset, dubbed ETHY-001, is scheduled to start this year. Ethyreal is developing the drug candidate for thyroid eye disease (TED) and Graves’ disease (GD).“These two conditions frequently coexist in the same individual, yet current treatments for GD do not treat or prevent TED, and conversely, TED treatments do not address the hyperthyroidism characteristic of GD,” Ethyreal CEO Niranjan Kameswaran, Ph.D., said in a statement.Amgen markets Tepezza in TED. With an FDA approval decision due this month, Viridian Therapeutics is at the front of a pack of companies aiming to compete with Amgen’s blockbuster. Tepezza and Viridian’s veligrotug both target IGF-1R. The GD pipeline includes argenx’s efgartigimod, Biohaven Therapeutics’ BHV-1300, Immunovant Sciences’ IMVT-1402 and Sanofi’s rilzabrutinib. Ethyreal has identified TSHR blockade as a way to treat TED and GD. By stopping autoantibodies from activating the receptor, the biotech aims to treat TED symptoms in the eye while tackling GD by reducing excess thyroid hormone production in thyroid cells.Other companies are pursuing similar approaches. Changchun GeneScience Pharmaceutical advanced an anti-TSHR antibody into the clinic and sold ex-China rights to the candidate to Yarrow Bioscience for $70 million upfront. Ollin Biosciences also entered the space by partnering with a Chinese biotech, agreeing to a financial package worth up to $440 million for rights to VelaVigo Bio’s TSHRxIGF-1R bispecific.  The TSHR race includes oral antagonists. Crinetics Pharmaceuticals and Septerna have shared preclinical data on “nonpeptide” and small molecule TSHR antagonists, respectively, in recent years, although both biotechs are focused on other programs.Ethyreal will share more information on its contender next week at the Endocrine Society’s 2026 Annual Meeting. The presentation will cover preclinical data on an anti-TSHR antibody with half-life extension technology that is designed for subcutaneous administration using an autoinjector. Ethyreal has taken the asset toward the clinic using the proceeds of previously undisclosed series A and B rounds.

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference : Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY Goldman Sachs 47th Annual Global Healthcare Conference : Fireside chat on Tuesday, June 9, 2026, at 4:00pm ET in Miami, FL A live webcast of each presentation can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. A replay will be available following each event. About Viridian Therapeutics Viridian is a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for patients with autoimmune and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for validated drug targets and disease-driving mechanisms in autoimmune and rare diseases. Viridian is advancing multiple late-stage, anti-insulin-like growth factor-1 receptor (IGF-1R) candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company conducted a pivotal program for veligrotug, including two global phase 3 clinical trials, THRIVE and THRIVE-2, to evaluate its efficacy and safety in patients with active and chronic TED. THRIVE and THRIVE-2 reported positive topline data, meeting their primary endpoints and all secondary endpoints. Viridian is also advancing elegrobart as the potential first subcutaneous autoinjector for the treatment of TED. Viridian is conducting an ongoing pivotal program for elegrobart, including two global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of elegrobart in patients with active and chronic TED. REVEAL-1 and REVEAL-2 reported positive topline data, meeting their primary endpoints and multiple secondary endpoints. In addition to its IGF‑1R inhibitor portfolio, Viridian is developing an anti–thyroid‑stimulating hormone receptor (TSHR) program designed as a potential therapy for TED and Graves’ disease. Viridian is also advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which have the potential to be developed in multiple autoimmune diseases. Viridian is based in Waltham, Massachusetts. For more information, please visit . Follow Viridian on LinkedIn and X . Contacts Investors Greg Rossino grossino@viridiantherapeutics.com Media Lisa Lopez llopez@viridiantherapeutics.com